Abstract
Pivotal Immune-Bridging Study of the Inactivated Whole-Virus COVID-19 Vaccine VLA2001: A Phase 3, Randomized Controlled Clinical Trial in Adults Using Adenoviral Vector Vaccine AZD1222 as a Comparator
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
